Drug Trial Radar · NCT04667013
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Sep 1, 2028
Primary completion
Mar 31, 2029
Study completion Aug 30, 2029
Sponsor
- Lead sponsor
- Guangzhou Magpie Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (i.e. how study drug is taken up by the body) of TBN in healthy participants.
Conditions
- Healthy
Interventions
Tetramethylpyrazine nitrone (TBN) tablet / PlaceboDrug
Subjects will be administered multiple oral doses of TBN or matching placebo tablets twice a day for 6 consecutive days and a last dose in the morning of Day 7.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs)Time frame: 14 days
- Assessment of physical examination.Time frame: 14 days
- Assessment of vital signs.Time frame: 14 days
- Assessment of 12 lead-ECG.Time frame: 14 days
- Assessment of urine pregnancy.Time frame: 14 days
- Assessment of Clinical Laboratory Tests.Time frame: 14 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.